Quick Answer
ZyVersa Therapeutics, Inc. reported Operating Income of -$25.49 million for fiscal year 2025.
ZyVersa Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$25.49M | -179.0% |
| 2024 | -$9.14M | +91.5% |
| 2023 | -$107.75M | -13039.7% |
| 2022 | -$820.1K | +93.7% |
| 2022 | -$13.01M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.75M | -814.3% | -915.2% |
| June 30, 2025 | -$2.04M | +25.8% | +4.7% |
| March 31, 2025 | -$2.14M | +24.1% | +5.5% |
| September 30, 2024 | -$2.27M | +21.8% | +17.6% |
| June 30, 2024 | -$2.75M | +96.8% | +2.6% |
| March 31, 2024 | -$2.83M | +38.4% | +2.6% |
| September 30, 2023 | -$2.90M | -194.5% | +96.6% |
| June 30, 2023 | -$86.33M | -17208.2% | -1779.9% |
- ZyVersa Therapeutics, Inc. showed a decrease of -179.0% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, ZyVersa Therapeutics, Inc.’s operating income has declined by 95.9% (from -$13.01 million to -$25.49 million).
- The most recent figure is from ZyVersa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: